Suppression of adrenal function in children with acute lymphoblastic leukemia following induction therapy with corticosteroid and other cytotoxic agents.
OBJECTIVE
To evaluate adrenal function in children with acute lymphoblastic leukemia (ALL) after induction therapy with corticosteroid and other cytotoxic agents. Study design Children with ALL (N=24) were treated with prednisolone (40 mg/m(2) per day) for 28 days during the induction phase followed by 1 week of oral dexamethasone every 4 weeks. A low-dose (1 microg) adrenocorticotropin (ACTH) test was performed 2 weeks after discontinuation of prednisolone; it was repeated 2 weeks later and then every 4 weeks in patients with adrenal suppression until normal response was achieved.


RESULTS
Adrenal suppression was found in 46% of patients at 2 weeks after discontinuation of prednisolone; it persisted in 38%, 29%, and 13% of patients through 4 weeks, 8 weeks, and 20 weeks, respectively. Adrenal suppression appeared to last significantly longer in children aged >or=5 years than in children aged <5 years. Four children developed febrile neutropenia; all belonged to the adrenal suppressed group and were unable to mount an adequate adrenal response to the stress.


CONCLUSIONS
About 50% of children with ALL developed adrenal suppression 2 weeks after a 4-week induction therapy with prednisolone. The suppression could persist through 20 weeks and may hinder an adequate adrenal response during acute febrile illness.
Mahachoklertwattana
Pat
P
Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand. rapmw@mahidol.ac.th
Vilaiyuk
Soamarat
S
Hongeng
Suradej
S
Okascharoen
Chusak
C
D000293:Adolescent; D000309:Adrenal Insufficiency / Q000139:chemically induced* / Q000453:epidemiology; D000324:Adrenocorticotropic Hormone; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003907:Dexamethasone / Q000009:adverse effects; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects; D007223:Infant; D008297:Male; D009503:Neutropenia / Q000453:epidemiology; D010913:Pituitary-Adrenal System / Q000187:drug effects; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011239:Prednisolone / Q000009:adverse effects*; D018709:Statistics, Nonparametric; D016019:Survival Analysis; D013785:Thailand / Q000453:epidemiology
D018931:Antineoplastic Agents, Hormonal; D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D011239:Prednisolone; D006854:Hydrocortisone